GROWTH HORMONE TREATMENT IN A PATIENT WITH LANGER MESOMELIC DYSPLASIA by Maggio, M. et al.
19750th Annual Meeting of the ESPE 
__________________________________________________ _____________________________________________________________________
Horm Res 2011;76(suppl 2)
______________________________________
P2-d1-630 GH and IGF Treatment 1
Accurate long-term prediction of height 
development during growth hormone (GH) 
treatment in prepubertal children with growth 
(TS)
Michael B. Ranke1; Anders Lindberg2; Mathias Brosz3; Stefan Kaspers4; 
Jane Loftus5; Hartmut Wollmann4; Maria Koltowska-Haggstrom2; 
Mathieu Roelants6
1University Children’s Hospital, Paediatric Endocrinology, Tuebingen, 
Germany; 2
Outcomes, Stockholm, Sweden; 3StatConsult, Gesellschaft für 
klinische und Versorgungsforschung mbH, Magdeburg, Germany; 
4
Kingdom; 5
6Free University Brussels, Laboratory of Anthropogenetics, Brussels, 
Belgium
Background: Treatment with GH during the pre-pubertal years is essential 
for improvement of the height outcome of short children. Optimizing and 
individualizing GH therapy requires the accurate simulation of height devel-
opment based on empirical growth prediction models early during the course 
of treatment.
Methods: Pre-pubertal children with idiopathic GHD or TS documented 
step, cohorts which had previously been used to develop models for the pre-
treatment were analyzed and a prediction algorithm for the annual gain in 
weight for an observed gain in height was developed. In a second step, the 
664 GHD and 607 TS patients from GH start up to 4 prepubertal years). The 
most likely height development was simulated prospectively by sequential 
-
isting yearly prediction algorithms for HV.
Results: When height was simulated from GH start in GHD, the predicted 
height was 30.0 (5.0) cm. In TS the corresponding predicted and observed 
mean gains were 27.2 (2.2) cm and 26.5 (3.8) cm respectively. The simula-
tion model was predictive in all but 22 (3.3%) of the 664 cases of the GHD 
validation cohort from GH start. This proportion was below 2% for all of the 
Conclusion: Sequential application of annual prediction models permits ac-
treatment in GHD and TS. The system is applicable for groups from GH start 
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Background: Léri Weill syndrome (LWS) is a pseudoautosomal inherited 
skeletal dysplasia being associated with SHOX -
short stature and a characteristic dysostosis of the wrist (Madelung defor-
patients is comparable to that of patients with Turner syndrome.
Objective and hypotheses: 
to a X/Y translocation and contiguous gene syndrome with lack of the SHOX, 
with a height of 122.9 cm (- 3.3 SDS), facial dysmorphism, mental retardation 
and ichthyosis. Chromosomal analysis revealed a deletion of Xp including 
the PAR with translocation of the duplicated Yq to the X chromosome. Af-
height of 145.9 (-3.8 SDS). Two adult sisters of the patient had the same chro-
mosomal aberration and presenting with short stature (-2.6 and -2.0 SDS), 
but lacking ichthyosis and mental retardation. Altogether they have 3 affected 
sons, which are treated with GH starting at Tanner stage 1.
Results: In boy 1 treatment started at age 5.7 years (height -2.7 SDS). After 
2.2 years height SDS gain was 0.7. Boy 2 was treated from age 4.5 years 
(height -2.2 SDS) for two years when a gain in height SDS of 0.8 was noted. 
In boy 3 treatment started at age 2.3 years (height -3.5 SDS). After 1.1 years 
on GH height SDS gain was 0.5.
Conclusions: The improvement of height SDS by GH substitution in these re-
ported cases of familiar LWS depended on the age of initiation of GH therapy. 
height in these young patients will be comparable to those shown in a former 
SDS was demonstrated.
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Background: -
-
sion of the SHOX gene in growing skeletal tissue of distal femur and tibia, 
ulna and radius has been detected.
Objective and hypotheses: -
deformities.
Methods: He was surgically treated for the scoliosis and at the age of 4 years, 
on the basis of genetic diagnosis of SHOX gene homozygous mutation, he 
started the treatment with GH for the poor growth, at the mean dose of 0,045 
mg/kg/die.
Results: The growth velocity of the patient evidenced an improvement in the 
of height velocity in the following years. At the age of 12 years his pubertal 
stage is PH2G2, his testicular volume 4 ml, his growth velocity is < 1 cm/year. 
The stature is 130 cm; the weight 30 kg. For the failure to achieve growth 
improvement, he stopped GH treatment. During the follow up however there 
was no worsening of the skeletal deformities.
Conclusions: Only a few cases of patients with homozygous mutation of 
SHOX gene treated with GH are described in the international literature. In a 
case with combined Turner syndrome and a deletion in the normal X chromo-
homozygous mutation of the SHOX gene, even if not treated with GH. Hence 
these patients may not improve their linear growth with GH treatment.
